Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Demonstrates Long-Term Growth Potential At 8.3% CAGR

The market for sodium glucose cotransporter 2 (SGLT2) inhibitors is on track for significant expansion in the coming years, driven by several factors including increasing awareness of their cardiovascular and renal benefits. This promising outlook reflects growing demand from an aging diabetic population and innovations in drug development that continue to open new pathways for treatment.

Projected Growth and Market Size of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
The SGLT2 inhibitors market is expected to reach a value of $16.35 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.3%. Key contributors to this growth include the recognition of cardio-renal advantages offered by these drugs, a rise in the elderly diabetic population, broader insurance reimbursements, introduction of new therapies, and deeper penetration into emerging markets. Notable trends shaping the market during this period include expanding application beyond diabetes care, increased use of combination therapies, growing adoption for heart failure treatment, enhanced safety profiles, and greater inclusion in clinical guidelines.

The sodium glucose cotransporter 2 (sglt2) inhibitors market size has grown strongly in recent years. It will grow from $10.96 billion in 2025 to $11.87 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising type 2 diabetes cases, unmet glycemic control needs, clinical trial success, physician awareness, regulatory approvals.

Download a free sample of the sodium glucose cotransporter 2 (sglt2) inhibitors market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Players Driving the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
The competitive landscape of the SGLT2 inhibitors market is dominated by several well-established pharmaceutical companies, including Johnson & Johnson Inc., Merck & Co Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma Inc, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co Ltd, Taisho Pharmaceutical Holdings Co Ltd, Lupin Limited, Glenmark Pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co Ltd, Kotobuki Pharmaceutical Co Ltd, Lexicon Pharmaceuticals Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Hanmi Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, and Mitsubishi Tanabe Pharma Corporation.

In a notable development in October 2024, Viatris Inc., a global healthcare company based in the US, signed an exclusive licensing agreement with Lexicon Pharmaceuticals to commercialize sotagliflozin outside the US and Europe. This partnership aims to expand access to the drug, improve treatment options for diabetic patients, and promote innovation in diabetes care worldwide. Lexicon Pharmaceuticals is recognized for its expertise in creating novel therapies targeting metabolic conditions.

View the full sodium glucose cotransporter 2 (sglt2) inhibitors market report:
https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends and Opportunities in Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
A major focus for companies in the SGLT2 inhibitors space is the development of dual inhibitor therapies that target both SGLT1 and SGLT2 proteins simultaneously. These combined therapies aim to optimize blood sugar control and improve outcomes in related conditions such as heart failure and diabetes.

For example, in May 2023, Lexicon Pharmaceuticals received FDA approval for sotagliflozin, a first-of-its-kind dual inhibitor designed to be taken once daily. This medication is intended to reduce cardiovascular death, hospitalizations due to heart failure, and urgent heart failure visits among adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Sotagliflozin works by lowering renal glucose and sodium reabsorption, which results in decreased preload and afterload on the heart and reduced sympathetic nervous system activity.

Market Segmentation Overview for Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
This market is categorized into several segments based on type, route of administration, and end-user.

By type, the market includes Invokana, Jardiance, Farxiga (also known as Forxiga), and Suglat. Each of these has subcategories such as generic and branded versions-Invokana is divided into Generic Invokana (Canagliflozin) and Branded Invokana, Jardiance into Generic Jardiance (Empagliflozin) and Branded Jardiance, Farxiga into Generic Farxiga (Dapagliflozin) and Branded Farxiga, and Suglat is further classified for its use in diabetes and heart failure treatment.

Regarding administration routes, oral delivery dominates, with other methods also considered. End-users encompass hospitals, homecare settings, and clinics, reflecting the diverse treatment environments where these inhibitors are applied.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.